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Abstract 
 Melanoma is one of the most aggressive types of skin cancer and its 
incidence rate is still increasing. All existing treatments are minimally effective. 
Consequently, new therapeutic agents for melanoma treatment should be 
developed. The DM-1 compound is a curcumin analog that possesses several 
curcumin characteristics, such as antiproliferative, antitumor and antimetastatic 
properties. The aim of this study was to evaluate the different signaling 
pathways involved in the cytotoxic effect of DM-1 on melanoma cells.  
 The apoptotic process and cytoskeletal changes were evaluated by 
immunoblotting and immunofluorescence, respectively, in melanoma cells.  
 After DM-1 treatment, SK-MEL-5 melanoma cells showed actin filaments 
disorganization with spicules formation throughout the cytoskeleton and 
significant reduction of focal adhesion as well as they were present only at cell 
extremities, conferring a poor connection between the cell and the substrate. 
Besides this, there was significant filopodium retraction and loss of typical 
cytoskeleton scaffold. These modifications contributed to cell detachment 
followed by cell death. 
 Furthermore, DM-1-induced apoptosis was triggered by multiple Bcl-2 
proteins involved in both the extrinsic and the intrinsic apoptotic pathways. SK-
MEL-5 cells showed a death mechanism mainly by Bcl-2/Bax ratio decrease, 
whereas A375 cells presented apoptosis induction by Mcl-1 and Bcl-xL down-
regulation. In SK-MEL-5 and A375 melanoma cells, there were a significant 
increase in the active form of caspase 9 and the inactive form of the effector 
caspase 3 was decreased in both cell lines. Expression of cleaved Parp was 
increased after DM-1 treatment in these melanoma cell lines, demonstrating 
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that the apoptotic process occurred. Altogether, these data elucidate the cellular 
and molecular mechanisms involved in the cytotoxicity induced by the antitumor 
agent DM-1 in melanoma cells.    
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adhesion 
 
Introduction 
Melanoma is one of the most aggressive types of skin cancer and its 
incidence rate is still increasing. Until now, no agent has been shown to improve 
survival over supportive care and treatment guidelines recommend that patients 
with metastatic disease enter into clinical trials [1]. 
Dacarbazine has been the standard therapy for metastatic melanoma for 
many years [2], but only around 10% of patients have objective tumor response 
and median overall survival is little more than 6 months [3,4]. This 
unsatisfactory treatment outcome encourages additional studies on novel 
therapeutic molecules, delivery systems and combination therapies for 
melanoma [5]. 
Curcumin has long been known as a chemo-preventive and 
chemotherapeutic agent and in vivo studies with curcumin have demonstrated 
decreased tumorigenesis in many organs [6], including antiproliferative effects 
in melanoma [7]. Because of its lack of toxicity, there has been increasing 
interest in further studies with curcumin [8,9]. Unfortunately, its low potency and 
poor absorption undermine its clinical potential [10]. 
 DM-1 is a curcumin analog and has previously been studied in animal 
models, such as melanoma and Ehrlich ascites tumor in mice. This compound 
is a powerful antitumor agent with both antimetastatic and antiproliferative 
activities. Interestingly, its pharmacological activity is restricted to tumor tissue, 
with minimal side effects on the normal surrounding tissue [11,12]. This may be 
explained by the high selectivity that DM-1 shows for cancerous cells without 
significant cytotoxic effect on normal cells [13].  
 Most of the currently used chemotherapeutic drugs exert its antitumor 
effect by activating a programmed cell death called apoptosis. This process can 
be triggered by many different stimuli, such as DNA damage, serum deprivation 
or incorrect cell-extracellular matrix (ECM) attachment, being the latter known 
as Anoikis [14]. The apoptotic process can be carried out by the extrinsic and/or 
the intrinsic pathways. The key regulator proteins of the intrinsic pathway are 
the Bcl-2 family proteins. Once the pro-apoptotic proteins are released from the 
complexes that form with the anti-apoptotic Bcl-2 proteins, the mitochondrial 
membrane outer permeabilization occurs, leading to the efflux of several 
apoptogenic factors to the cytosol [15]. This induces the activation of specific 
proteinases called caspases and, subsequently, the cleavage of many key 
proteins provoking the cell death [16]. In this work we try to elucidate the 
molecular mechanisms that participate in the apoptotic process induced by DM-
1 in human melanoma cell lines as well as analyze some morphological 
changes due to alterations in cytoskeletal structures related to cellular adhesion 
and migration.   
 
Materials and methods 
Cell lines and culture conditions 
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 Tumor cell lines of human melanoma (SK-MEL-5 and A375) were 
purchased from the American Type Culture Collection (Manassas, VA). These 
cells were grown with DMEM (Biological Industries, Beit Haemek, Israel) 
supplemented with 10% heat-inactivated fetal bovine serum (Life Technologies, 
Carlsbad, CA), 100 U/ml penicillin, 100 µg/ml streptomycin, and 2 mM L- 
glutamine all from Biological Industries. Cells were grown at 37 ºC in a 5% CO2 
atmosphere.  
 
DM-1: Sodium 4-[5-(4-hydroxy-3-methoxyphenyl)-3- oxo-penta-1,4-dienyl]-
2-methoxy-phenolate 
 Dried sodium ethanolate (0.01 mol) was mixed with 1,5-bis(4-hydroxy-3-
methoxyphenyl)-1,4-pentadien-3-one [17] (0.01 mol; 3.26 g) in a 1:1 molar ratio 
and stirred at room temperature under anhydrous reaction conditions, followed 
by solvent rotoevaporation until solidification. The compound C19H17O5Na has 
348 of molecular weight (Fig.1A). Results of the structural characterization of 
the isolated compound were the same as described previously by our group 
[18,19]. 
 
Cell viability assay (MTT assay) 
Cell viability was determined using MTT assay [20]. Cells were plated in 
triplicate wells (1 x 105 cells/well) in 100 µL of growth medium in 96-well plates 
and treated with increasing concentrations of DM-1 (1-100 µM) or drug diluent 
(DMSO). After 24 h incubation with DM-1, 10 µL of MTT (Sigma Chemical Co., 
St. Louis, MO) was added to each well for an additional 4 h. The blue MTT 
formazan precipitate was then dissolved in 100 µL of isopropanol: 1N HCl 
(24:1). The absorbance at 570 nm was measured on a multiwell plate reader. 
Cell viability was expressed as a percentage of control and IC25 or IC50 
represents the concentration of drug causing respectively, 25% or 50%, 
inhibition of the increase in absorbance compared with control cells. Data are 
shown as the mean ± standard deviation (s.d.) of three independent 
experiments. 
 
Morphological changes and filopodium retraction analysis by optical 
microscopy  
 The human melanoma cells SKMEL-5 (2 x 105 cells/mL) were cultured 
24 h with DMEM supplemented with 10% FBS before treatment. Cells were 
treated with DM-1 at 75 µM (IC50 value) for 90 min. During this period, 
temperature and CO2 cell culture conditions were maintained and phase 
contrast images were obtained from cell cultures with phase contrast 
microscope (Zeiss ApoTome) (Carl Zeiss, Jena, Germany) at time 0 and 90 min 
of DM-1 treatment for the analysis of filopodium retraction and cell morphology 
changes. 
 
Cytoskeleton analysis by fluorescence microscopy 
 Cells adhere to the substrate through the focal contacts establishing 
therewith. By immunofluorescence assay, using vinculin as a focal contacts 
marker, we analyzed the DM-1 capacity in inducing loss of these contacts and, 
hence, the cell de-adhesion. 
 SK-MEL-5 melanoma cells (2 x 105 cells/mL) were grown in a 24-well 
plate containing glass coverslips (20 x 20 mm). After treatment with DMSO 
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(control) or DM-1 (IC50) for 90 min, cells were fixed with 4% paraformaldehyde 
for 10 min at room temperature, before 0.5% Triton-x-100 permeabilization. 
Then, cells were incubated with 1% albumin in phosphate buffered saline (PBS) 
(w/v) for 15 min, and afterwards they were incubated with primary antibodies: 
anti-vinculin (1:400 dilution) (Sigma Chemical Co.) for 30 min at 37 ºC. 
Secondary antibody Cy3 goat anti-mouse (Jackson ImmunoResearch, Inc.) was 
used at 1:50 dilution. Simultaneously to secondary antibody incubation, cells 
were incubated with Bodipy Fl Phallacidin (Invitrogen, Carlsbad, CA) at 1:50 
dilution for 30 min at 37ºC for actin staining. After fixing cells with Mowiol 
(Sigma–Aldrich Chemical Co, St Louis, MO), samples were dried at 4ºC 
protected from light. Images were obtained using a Nikon eclipse E800 
microscopy. 
 
Western blot 
SK-MEL-5 and A375 melanoma cells (2 x 105 cells/mL) were exposed to 
DM-1 IC25 (75 and 65 µM DM-1, respectively) for 3, 6 or 24 h. They were then 
washed with PBS prior to the addition of lysis buffer ( 0.1% SDS, 1% NP-40, 
0.5% sodium deoxycholate, 50 mM NaF, 40 mM β-glycerophosphate, 200 µM 
sodium orthovanadate, 1 mM phenylmethylsulfonyl fluoride, serin and cystein 
protease inhibitor cocktail (Roche 11836170001)). After that, 40 µg protein 
extracts were separated by SDS-PAGE on a 10-15% polyacrylamide gel and 
transferred to Immobilon-P membranes (Millipore, Bedford, MA). Blots were 
blocked in 5% dry milk diluted in TBS-T (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 
0.1% Tween-20) for 1 h and then incubated overnight with primary antibodies. 
Antibodies were obtained from the following sources: anti-caspase 3 (Cat#sc-
1225), anti-Bcl-2 (B-cell lymphoma 2) (Cat#sc-492), anti- Mcl-1 (Induced 
myeloid leukemia cell differentiation protein) (Cat#sc-69840), anti-Bak (Bcl-2 
homologous antagonist/killer) (Cat#sc-1035) and anti-Bcl-xL (B-cell lymphoma-
extra large)(Cat#sc-634) were from Santa Cruz Biotechnologies (Santa Cruz, 
CA); anti-caspase 9 (Cat#9501), anti-Parp (Poly ADP ribose 
polymerase)(Cat#9542), anti-Bax (Bcl-2-associated X protein)(Cat#2772) and 
anti-Bid (BH3 interacting domain death agonist) (Cat#2002) were from Cell 
Signaling Technology (New England Biolabs, Hertfordshire, UK); anti-Vinculin 
(Cat#9131, Sigma Chemical Co.). All primary antibodies were used according to 
the manufacturer’s instructions. Antibody binding was detected with the 
appropriated secondary antibodies conjugated to horseradish peroxidase, and 
signals were detected using enhanced chemiluminescence detection kit 
(Amersham, Buckinghamshire, UK). Protein bands were quantified with the 
image analysis software program MacBiophotonics Image-J 1.43m. Results 
were presented as normalized fold change respect control. Normalization has 
been done using vinculin as a loading control.  
 
Statistical analysis 
 Results are expressed as mean ± s.d. Data were analyzed using one-
way analysis of variance (ANOVA) and significant mean differences were 
determined using multiple comparisons by the TUKEY-KRAMER test at the 
p<0.05 level. Significant differences between the control and treated groups are 
indicated by ***p<0.001, **p<0.01 and *p<0.05.  
 
Results 
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Effect of DM-1 on cell viability 
 The antiproliferative effect of DM-1 (Fig 1A) was determined using the 
MTT reduction assay in human melanoma cell lines. Fig. 1B shows DM-1 
effects on cell viability after 24 h of drug exposure, ranging from 0 to 100 µM of 
this compound. Cell viability was significantly decreased in both tumor cells. In 
SK-MEL-5 melanoma cells, IC25 and IC50 values were 36 and 75 µM, 
respectively. In A375 melanoma cells, IC25 and IC50 values were 37 and 65 µM, 
respectively. Altogether, DM-1 shows a significant cytotoxicity in human 
melanoma cells. 
 
Cytoskeleton changes and reduction in the number of focal adhesions 
after DM-1 treatment 
 Cellular morphological changes after DM-1 treatment were observed. To 
evaluate whether anchorage-dependent cell detaching from the extracellular 
matrix was participating in DM-1 cytotoxicity, cytoskeleton reorganization and 
number of focal adhesions were analyzed. Cytoskeleton of non-treated SK-
MEL-5 melanoma cells presented aligned actin filaments, clearly defined and 
organized. The focal adhesions, which are the dynamic link between the 
cytoskeleton and ECM proteins, showed up in large number and spread 
throughout the cell in non-treated cells (Fig. 2A). After DM-1 treatment, SK-
MEL-5 melanoma cells showed actin filaments disorganization with spicules 
formation throughout the cytoskeleton and significant reduction of focal 
adhesion as well as they were present only at cell extremities, conferring a poor 
connection between the cell and the substrate (Fig. 2B). 
 
 Filopodia are thin, actin-rich plasma-membrane protrusions involved in 
cell migration [21]. Filopodium retraction in SK-MEL-5 melanoma cells was 
evaluated after DM-1 treatment for 90 min (Fig. 3). There was significant 
filopodium retraction and loss of typical cytoskeleton scaffold. The control group 
did not present notably differences after 90 min of diluent treatment. All in all, 
these results indicate that cells start to detach after 90 min of DM-1 treatment 
and this may be a signal to activate cell death. 
 
 
Bcl-2 family of proteins are involved in DM-1-induced apoptosis  
 
To elucidate what molecular mechanisms were participating in DM-1-
induced apoptosis, Bcl-2 family proteins were analyzed. The protein expression 
level of anti-apoptotic proteins (Bcl-2, Mcl-1, Bcl-xL and Bid) and pro-apoptotic 
proteins (Bax and Bak) was studied by immunoblotting assays in two human 
melanoma cell lines, SK-MEL-5 and A375. As we can observe in Fig 4, most of 
the anti-apoptotic proteins decreased their levels upon DM-1 exposure whilst 
the pro-apoptotic members increased or remain stable. 
 
 The ratio among the anti and the pro-apoptotic family members is critical 
to regulate the apoptotic process. To establish whether DM-1 regulated the Bcl-
2/Bax ratio, we measured the levels of both proteins in lysates of SK-MEL-5 and 
A375 melanoma cells, treated with or without IC25 value (75 and 65 µM DM-1, 
respectively) for 24 h. We found that DM-1 increased the levels of Bax (pro-
apoptotic) and generally decreased the levels of Bcl-2 (anti-apoptotic) at all 
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treatment times (3, 6 and 24 h) in SK-MEL-5 cell line. This effect was observed 
only after 24 h of DM-1 treatment in A375 cell line. Consequently, the Bcl-2/Bax 
ratio was greatly reduced in all SK-MEL-5 samples treated with DM-1 compared 
to control cells and only in the last time point for A375 cell line (Fig 5 A and B).  
 On the other hand, Mcl-1 was down-regulated at all treatment times in 
A375 melanoma cell line, but this effect was not observed in SK-MEL-5 
melanoma cell line, that showed Mcl-1 decrease only after 24 h of DM-1 
treatment (Fig. 5 C). DM-1 did not affect expression of pro-apoptotic member 
Bak in both melanoma cell lines so the ratio Mcl-1/Bak was also decreased (Fig 
5 D).  
 Furthermore, only A375 melanoma cell line had Bcl-xL down-regulation 
after 24 h of DM-1 treatment. This anti-apoptotic protein was not modified in SK-
MEL-5 melanoma cell line (Fig. 5 E). 
 Finally, the BH3-only protein Bid (inactive form) was decreased mainly in 
A375 melanoma cells treated with DM-1. SK-MEL-5 melanoma cells only 
presented Bid decrease after 24 h of DM-1 treatment (Fig. 5 F). Anyway, this 
demonstrates that the extrinsic apoptotic pathway is activated at different points 
in each cell line.  
Altogether, these results confirm the participation of the pro-apoptotic 
Bcl-2 protein members in DM-1-induced apoptosis. 
 
Caspase activation and Parp degradation after DM-1 treatment 
 The apoptotic process was also analyzed by caspase activation (Fig. 6). 
In SK-MEL-5 melanoma cells, the inactive form of the initiating caspase 9 (pro-
caspase 9) was reduced from 3 h of DM-1 treatment with a high increase in the 
active form (cleaved caspase 9) after 24 h. A375 melanoma cells showed no 
notable proform decrease, however, after 24 h there was a significant increase 
in the active form of caspase 9. 
 Keeping on with the apoptotic pathway, the inactive form of the effector 
caspase 3 was decreased in both cell lines, and in SK-MEL-5 melanoma cells 
this reduction was started after 24 h. On the other hand, in A375 melanoma 
cells, caspase 3 proform decrease was remarkable from 3 h to 24 h of DM-1 
treatment. 
 Protein expression levels of cleaved Parp, a caspase substrate, were 
increased after DM-1 treatment in both melanoma cell lines. The higher 
increase of this marker was found after 24 h of DM-1 treatment, demonstrating 
that the apoptotic process has occurred. 
 
Discussion 
  
 The curcumin analog called DM-1 is a potent antitumor agent with proved 
antiproliferative and antimetastatic activities in animal models [11,12]. In this 
study we present the molecular mechanisms involved in its antitumor activity, 
analyzing in detail the type of cell death induced by DM-1. 
Cell growth, death and survival responses are the result of the integration 
of numerous chemical and biophysical signals from the cell’s surrounding 
environment. Interactions between the cell and the ECM are a major source of 
these environmental signals and ECM provides structural support by serving as 
a scaffold for cells [22]. The survival of adherent cells depends on an 
uninterrupted connection with the components of the ECM, such as laminin and 
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fibronectin [23]. The ability of cells to adhere to the ECM is a critical determinant 
of cytoskeletal organization and thus of cellular morphology [24]. Focal 
adhesions are specialized organelles that provide structural and functional 
continuity between the cytoskeleton and the underlying ECM [25] and are 
essential for survival of anchorage-dependent cells [26,27,28]. When ECM-
integrin interactions are disrupted, cells undergo apoptotic cell death. This 
adhesion dependent cell death is termed anoikis [29]. DM-1 induced actin 
filaments disorganization with cytoskeleton disarray in SK-MEL-5 melanoma 
cells. These factors, in combination with significant loss of cell-substrate focal 
adhesions, may induce cell detachment followed by death. Similarly, prostate 
tumor cells treated with curcumin also showed effects on actin filaments with 
impaired cytoskeletal dynamics [30].  
 It has been proved that curcumin rapidly arrests cell movements through 
the alteration of microfilament organization and function, which are critical for 
cell adhesion [31]. Filopodia and lamellipodia are cellular structures that 
possess the critical elements to assemble integrin-dependent adhesions. The 
responsible mechanisms for focal adhesions formation are not well understood, 
but probably depend on the physical state of the underlying actin scaffold, 
integrin-receptor spacing as well as biochemical signals [32]. Filopodia play an 
essential role during cell migration, cell-cell or cell-matrix adhesion, by initiating 
contacts and conveying signals to the cell cortex. Because their dynamics 
depend on a discrete number of actin filaments, filopodia provide a model of 
choice to study elementary events linked to adhesion and downstream signaling 
[33]. 
 SK-MEL-5 melanoma cells treated with DM-1 showed significantly 
cytoskeleton changes as filopodium retraction and loss of original scaffold. 
These modifications contributed to cell detachment followed by cell death. 
These effects in tumor cells treated with curcumin are triggered mainly by down-
regulation of focal adhesion kinase (FAK) co-related to detachment-dependent 
apoptosis (anoikis) [34] or by integrin α6β4 inhibition which is correlated with 
tumor cell proliferation and anchorage-independent growth. This integrin 
mobilizes lamellipodia and filopodia, besides it interacts with growth factor 
receptors, leading to interaction with the actin cytoskeleton [35]. 
At the molecular level, pro-apoptotic members of the Bcl-2 family, Bax 
and Bak, play crucial but predominantly functionally redundant roles in the 
mitochondria-dependent apoptosis pathway induced by numerous apoptotic 
stimuli downstream from BH3-only proteins [36]. Pro-survival protein Mcl-1 is 
considered to preferentially restrict the activation of Bak but not Bax [37,38], 
whilst Bcl-2 inactivates Bax. Previous publications reported that some apoptotic 
stimulus induced apoptosis via a Bak-dependent pathway by accelerating the 
degradation of Mcl-1 [37,39,40,41]. 
Curcumin is known to induce the up-regulation of pro-apoptotic proteins 
of the Bcl-2 family and the down-regulation of anti-apoptotic proteins Bcl-2 and 
Bcl-xL in melanoma cells [42]. In this work, apoptosis was evaluated by anti-
apoptotic and pro-apoptotic protein expression levels in two different melanoma 
cell lines. SK-MEL-5 melanoma cells treated with DM-1 showed Bcl-2/Bax ratio 
decrease after 3, 6 and 24 h of treatment, but expression of Mcl-1 and inactive 
Bid was diminished only after 24 h. Another curcumin analog, 
dimethoxycurcumin, induces Bcl-2 down-regulation and Bax up-regulation in 
breast tumor cells [43].  
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In SK-MEL-5 cell line, Bak protein expression was not modified, but Bax 
protein expression was significantly increased after DM-1 treatment. Activated 
pro-apoptotic proteins like Bid and Bax cause the release of the apoptogenic 
cytochrome-c from the mitochondrial membrane, leading to caspase cascade 
activation [44]. DM-1 also induces cytochrome-c release and electric 
mitochondrial membrane potential decrease in B16F10 melanoma cells after 6 
h of treatment [13]. 
A375 melanoma cells showed some alterations in response to DM-1 
treatment in comparison to SK-MEL-5 cells. A375 showed Bcl-2 decrease only 
after 24 h of DM-1 treatment, without Bax and Bak modifications at all studied 
times. The main mechanism of action was Mcl-1 and inactive Bid decrease at 3, 
6 and 24 h and Bcl-xL decrease only after 24 h, resulting in mitochondria-
mediated cell death, suggesting that apoptosis in SK-MEL-5 melanoma cells 
treated with DM-1 was not correlated with down-regulation of Bcl-xL. This is 
also the case of 5-fluouracil or paclitaxel treatment where the down-regulation 
of Bcl-XL is not observed in the apoptosis induced [45].  
 It is known that curcumin and curcumin analogs possess pro-apoptotic 
activity in many tumor cells as it was shown by cleaved caspase 3 increase in 
colon cancer [46] and breast cancer [12] or Parp cleavage in osteosarcoma 
cells [47]. Both melanoma cell lines showed cleavage of pro-caspase 9, pro-
caspase 3 (inactive form) and Parp (caspase substrate), as well as cleaved 
caspase 9 and cleaved Parp. These results were time-dependent and they were 
more relevant after 24 h of DM-1 treatment.  
 Some of the differences in DM-1 treatment response among several 
melanoma cell lines could be co-related to several factors such as the origin of 
tumor tissue, different protein expression and mutations. SK-MEL-5 melanoma 
cells are derived from a metastatic site in axillary node [48], whereas A375 
melanoma cells are derived from primary site in the skin [49]. For instance, 
A375 melanoma cells express wild-type p53 [50] and, although SK-MEL-5 
melanoma cells do not exhibit any p53 mutations, the absence of p21Waf1 
expression suggests functionally aberrant p53 [51]. Moreover, Placzek and 
coworkers showed a significantly up-regulation of Bcl-2 protein in several SK-
MEL melanoma cell lines [52] that could explain the Bcl-2 target in SK-MEL-5 
by DM-1 treatment. These particularities may explain the different pathways in 
cell death in these both tumor cells.  
 Furhermore, it was proven that DM-1 compound induces cell cycle arrest 
by cyclin D1 and Ki67 decrease and apoptosis by free radicals production, TNF-
R1 and cleaved caspase-8 increase, as well mitochondrial electrical potential 
decrease. Additionally, apoptosis was also confirmed by apoptotic bodies in 
human melanoma cell line. DM-1 antitumor therapy in vivo showed tumor 
burden decrease with DM-1 monotherapy or in combination with Dacarbazine, 
besides survival rate increase [13]. 
In conclusion, this study demonstrates that low concentrations of DM-1 
induce apoptosis triggered by multiple Bcl-2 proteins involved in both the 
extrinsic and the intrinsic apoptotic pathways. SK-MEL-5 cells showed a death 
mechanism mainly by Bcl-2/Bax ratio decrease, whereas A375 cells presented 
apoptosis induction by Mcl-1 and Bcl-xL down-regulation, suggesting multiple 
molecular mechanisms involved in melanoma treatment by DM-1. Furthermore, 
DM-1 treatment also induces changes in morphology and loss of cell-substrate 
contact, which may suggest cell death by Anoikis.   
 9
 
Acknowledgments 
The authors are grateful to Fundação de Amparo à Pesquisa do Estado 
de São Paulo (Fapesp 2008/56397-8; 2011/50435-8.), the Spanish government 
and the European Union (FIS-PI10/00338) for financial support. 
 
Conflict of interest: none 
 
References 
 
1. Maio M. Melanoma as a model tumour for immuno-oncology. Ann Oncol 
2012; 23: 10-4. 
 
2. Marsden JR, Newton-Bishop JA, Burrows L. Revised UK guidelines for 
management of cutaneous melanoma. Br J Dermatol 2010; 163: 238-56.  
 
3. Chapman PB, Einhorn LH, Meyers ML et al. Phase III multicenter 
randomized trial of the Dartmouth regimen versus dacarbazine in patients with 
metastatic melanoma. J Clin Oncol 1999; 17: 2745-51.  
 
4. Middleton MR, Grob JJ, Aaronson N et al. Randomized phase III study of 
temozolomide versus dacarbazine in the treatment of patients with advanced 
metastatic malignant melanoma. J Clin Oncol 2000; 18: 158-66. 
 
5. Lillehammer T, Engesaeter BO, Prasmickaite L et al. Combined treatment 
with Ad-hTRAIL and DTIC or SAHA is associated with increased mitochondrial-
mediated apoptosis in human melanoma cell lines. J Gene Med 2007; 9: 440-
51. 
 
6. Carvalho FR, Vassão RC, Nicoletti MA et al. Effect of Curcuma zedoaria 
crude extract against tumor progression and immunomodulation. J Venom Anim 
Toxins Incl Trop Dis 2010; 16: 324-41. 
 
7. Abusnina A, Keravis T, Yougbaré I et al. Anti-proliferative effect of curcumin 
on melanoma cells is mediated by PDE1A inhibition that regulates the 
epigenetic integrator UHRF1. Mol. Nutr. Food  Res 2011; 55: 1677-89. 
 
8. Rivera-Espinoza Y, Muriel P. Pharmacological actions of curcumin in liver 
diseases or damage. Liver Int 2009; 29: 1457-66. 
 
9. Bisht S, Maitra A. Systemic delivery of curcumin: 21st century solutions for an 
ancient conundrum. Curr Drug Discov Technol 2009; 6: 192-9. 
 
10. Shoba G, Joy D, Joseph T et al. Influence of piperine on the 
pharmacokinetics of curcumin in animals and human volunteers. Planta Med 
1998; 64: 353-6. 
 
11. Faião-Flores F, Pardi PC, Santos RP,et al. Antiproliferative and 
antimetastatic activity of DM-1, sodium 4-[5-(4-hydroxy-3-methoxyphenyl)-3-
 10
oxo-penta-1,4-dienyl]-2-methoxy-phenolate, in B16F10 melanoma. Applied 
Cancer Res 2008; 28: 72-9. 
 
12. Faião-Flores F, Suarez JA, Pardi PC et al. DM-1, sodium 4-[5-(4-hydroxy-3-
methoxyphenyl)-3-oxo-penta-1,4-dienyl]-2-methoxy-phenolate: a curcumin 
analog with a synergic effect in combination with paclitaxel in breast cancer 
treatment. Tumour Biol 2012; 33: 775-85.  
 
13. Faião-Flores F, Quincoces Suarez JA, Stuchi-Engler SM et al. The 
curcumin analog DM-1 induces apoptotic cell death in melanoma. Tumor Biol 
2013. Doi: 10.1007/s13277-013-0653-y  
 
14. Gilmore AP. Anoikis. Cell Death Differ 2005; 12: 1473-7. 
 
15. Willis SN, Fletcher JI, Kaufmann T et al. Apoptosis initiated when BH3 
ligands engage multiple Bcl-2 homologs, not Bax or Bak. Science 2007; 315: 
856-9. 
 
16. Green DR. Apoptotic pathways: ten minutes to dead. Cell 2005; 21: 671-4. 
 
17. Quincoces Suarez JA, Rando DG, Maria DA et al. Methods to prepare 
penta-1,4-dien-3-ones and substituted cyclohexanones and derivatives and 
derivatives with antitumoral and antiparasitic properties, the compounds and 
their uses. Brazilian Patent PI 0602640-0 (06.07.2006); PCT/ BR2007/000175 
(06.07.2007); WO 2008/003155. 
 
18. Quincoces Suarez JA, Maria DA, Faião-Flores F et al. Pharmaceutical 
composition and use of the pharmaceutical composition for the treatment, 
prophylaxis or prevention of neoplastic diseases in human and animals. 
Brazilian Patent: PI 0902039-0; 09/06/2009; PCTBR2009/000375; 11.11.2009; 
WO 2010/142007; 16/12/2010. 
 
19. Quincoces Suarez JA, Rando DG, Santos RP et al. New antitumoral agents 
I: In vitro anticancer activity and in vivo acute toxicity of synthetic 1,5-bis(4-
hydroxy- 3-methoxyphenyl)-1,4-pentadien-3-one and derivatives. Bioorg Med 
Chem 2010; 18: 6275–81. 
 
20. Mosmann T. Rapid colorimetric assay for cellular growth and survival: 
application to proliferation and cytotoxicity assays. J Immunol Methods 1983; 
65: 55-63. 
 
21. Mattila PK, Lappalainen P. Filopodia: molecular architecture and cellular 
functions. Nat Rev Mol Cell Biol 2008 9: 446-54. 
 
22. Ma Y, Halade GV, Lindsey ML. Extracellular Matrix and Fibroblast 
Communication Following Myocardial Infarction. J Cardiovasc Transl Res 2012 
doi: 10.1007/s12265-012-9398-z. 
 
23. Horiguchi M, Ota M, Rifkin DB. Matrix Control of Transforming Growth 
Factor-β Function. J Biochem 2012; 152: 321-9 
 11
 
24. Gumbiner BM. Cell adhesion: the molecular basis of tissue architecture and 
morphogenesis. Cell 1996; 84: 345-57. 
 
25. Burridge K, Fath K, Kelly T et al. Focal adhesions: transmembrane junctions 
between the extracellular matrix and the cytoskeleton. Annu Rev Cell Biol 1988; 
4: 487–525. 
 
26. Meredith JE, Schwartz MA. Integrins, adhesion and apoptosis. Trends Cell 
Biol 1997; 7: 146-50. 
 
27. Chen CS, Mrksich M, Huang, S et al. Geometric control of cell life and 
death. Science 1997; 276: 1425-8. 
 
28. Frisch SM, Ruoslahti E et al. Integrins and anoikis. Curr Opin Cell Biol 1997; 
9: 701-6. 
 
29. Murphy-Ullrich JE. The de-adhesive activity of matricellular proteins: is 
intermediate cell adhesion an adaptive state? J Clin Invest 2001; 107: 785-90. 
 
30. Shi Q, Wada K, Ohkoshi E et al. Antitumor agents 290. Design, synthesis, 
and biological evaluation of new LNCaP and PC-3 cytotoxic curcumin analogs 
conjugated with anti-androgens. Bioorg Med Chem 2012; 20: 4020-31.  
 
31. Wang Y, Chen Z, Xiao L et al. Evaluating cell migration in vitro by the 
method based on cell patterning within microfluidic channels. Electrophoresis 
2012; 33: 773-9.  
 
32. Wehrle-Haller B. Structure and function of focal adhesions. Curr Opin Cell 
Biol 2012; 24: 116-24.. 
 
33. Romero S, Quatela A, Bornschlögl T et al. Filopodium retraction is 
controlled by adhesion to its tip. J Cell Sci 2012 doi: 10.1242/jcs.104778. 
  
34. Banerji A, Chakrabarti J, Mitra A et al.Effect of curcumin on gelatinase A 
(MMP-2) activity in B16F10 melanoma cells. Cancer Lett 2004; 211: 235-42. 
 
35. Soung YH, Chung J. Curcumin inhibition of the functional interaction 
between integrin α6β4 and the epidermal growth factor receptor. Mol Cancer 
Ther 2011; 10: 883-91.  
 
36. Shimazu T, Degenhardt K, Kamal AN et al NBK/BIK antagonizes MCL-1 
and BCL-XL and activates BAK-mediated apoptosis in response to protein 
synthesis inhibition. Genes Develop 2007; 21: 929-41 
 
37. Willis SN, Chen L, Dewson G et al. Proapoptotic Bak is sequestered by Mcl-
1 and Bcl-xL, but not Bcl-2, until displaced by BH3-only proteins. Genes 
Develop 2005; 19: 1294-305. 
 
 12
38. Pearce AF, Lyles DS. Vesicular stomatitis virus induces apoptosis primarily 
through Bak rather than Bax by inactivating Mcl-1 and Bcl-XL. J Virol 2009; 83: 
9102–12. 
 
39. Gillissen B, Wendt J, Richter A et al. Endogenous Bak inhibitors Mcl-1 and 
Bcl-xL: differential impact on TRAIL resistance in Bax-deficient carcinoma. J 
Cell Biochem 2010; 188: 851-62. 
 
40. Wang YF, Jiang CC, Kiejda KA et al. Apoptosis induction in human 
melanoma cells by inhibition of MEK is caspase-independent and mediated by 
the Bcl-2 family members PUMA, Bim, and Mcl-1. Clin Cancer Res 2007; 13: 
4934-42.  
 
41. Du X, Youle RJ, FitzGerald DJ et al. Pseudomonas exotoxin A-mediated 
apoptosis is Bak dependent and preceded by the degradation of Mcl-1. Mol Cel 
Biol 2010; 30: 3444-52. 
 
42. Bill MA, Bakan C, Benson DM Jr et al. Curcumin induces proapoptotic 
effects against human melanoma cells and modulates the cellular response to 
immunotherapeutic cytokines. Mol Cancer Ther 2009; 8: 2726-35.  
 
43. Kunwar A, Jayakumar S, Srivastava AK et al. Dimethoxycurcumin-induced 
cell death in human breast carcinoma MCF7 cells: evidence for pro-oxidant 
activity, mitochondrial dysfunction, and apoptosis. Arch Toxicol 2012; 86: 603-
14.  
 
44. Emam H, Zhao QL, Furusawa Y et al. Apoptotic cell death by the novel 
natural compound, cinobufotalin. Chem Biol Interact 2012; 199:154-60. 
 
45. Wu S, Zhu H, Gu J et al. Induction of apoptosis and down-regulation of Bcl-
XL in cancer cells by a novel small molecule, 2[[3-(2,3- 
dichlorophenoxy)propyl]amino] ethanol. Cancer Res 2004; 64: 1110–3. 
 
46. Kanwar SS, Yu Y, Nautiyal J et al. Difluorinated-curcumin (CDF): a novel 
curcumin analog is a potent inhibitor of colon cancer stem-like cells. Pharm Res 
2011; 28: 827-38. 
 
47. Fossey SL, Bear MD, Lin J et al. The novel curcumin analog FLLL32 
decreases STAT3 DNA binding activity and expression, and induces apoptosis 
in osteosarcoma cell lines. BMC Cancer 2011; 11: 112. 
 
48. American Type Culture Collection, 2012. A375 CRL-1619™. Available:  
http://www.atcc.org/ATCCAdvancedCatalogSearch/ProductDetails/tabid/452/De
fault.aspx?ATCCNum=CRL-1619&Template=cellBiology. Accessed 29 august 
2012. 
 
49. American Type Culture Collection, 2012. SK-MEL-5 #HTB-70™. Available:  
http://www.atcc.org/ATCCAdvancedCatalogSearch/ProductDetails/tabid/452/De
fault.aspx?ATCCNum=HTB-70&Template=cellBiology. Accessed 29 august 
2012. 
 13
 
50. Min FL, Zhang H, Li WJ et al. Effect of exogenous wild-type p53 on 
melanoma cell death pathways induced by irradiation at different linear energy 
transfer. In Vitro Cell Dev Biol Anim 2005; 41: 284-8. 
51. Girnita L, Girnita A, Brodin B et al. Increased expression of insulin-like 
growth factor I receptor in malignant cells expressing aberrant p53: functional 
impact. Cancer Res 2000; 60: 5278-83. 
 
52. Placzek WJ, Wei J, Kitada S et al. A survey of the anti-apoptotic Bcl-2 
subfamily expression in cancer types provides a platform to predict the efficacy 
of Bcl-2 antagonists in cancer therapy. Cell Death Dis 2010; 1, e40. 
 
Figure legends 
 
Figure 1 – (A) Structure of DM-1; (B) DM-1 effect on cell viability after 24 h of 
drug exposure (from 3 to 100 µM) was analyzed by MTT assay. The linear 
regression curve and IC50 were calculated using Graph Pad Prism Instat 3 
software. The IC50 values estimated were 75 and 65 µM for SK-MEL-5 and 
A375 human melanoma cells, respectively.  
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Figure 2 – Cytoskeleton changes after DM-1 treatment analyze by fluorescence 
microscopy. (A) SK-MEL-5 melanoma cells were treated with DM-1 at 75 µM for 
90 min. Actin filaments are shown in green and focal adhesions (vinculin) in red. 
(B) Decrease of the number of focal adhesions is shown as a percentage 
respectively to control cells. The values are expressed as mean ± s.d. 
Significance are indicated by **p<0.01.   
 
Figure 3 – DM-1 induced morphological changes in SK-MEL-5 melanoma cells. 
Filopodium retraction (red arrows) were monitorized for 90 min after DM-1 
treatment at 75 µM. Images were obtained with phase contrast microscope 
(Zeiss Apoptome).  
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Figure 4 – Involvement of anti and proapoptotic members in SK-MEL-5 and 
A375 melanoma cell death. Total extracts were used to analyzed Bcl-2, Bcl-xL, 
Mcl-1, Bak, Bax and Bid protein levels after DM-1 treatment at 3, 6 and 24 h. 
Vinculin was used as a loading control.  
 
Figure 5 – Effect of DM-1 treatment on anti and pro-apoptotic members 
Expression in SK-MEL-5 and A375 melanoma cells. The cells were treated for 
3, 6, and 24 h with respectively DM-1 IC50 and fold changes of protein 
expression with respect to control cells were determined by quantitative 
densitometry using Image J software. The columns (mean ± s.d) are mean of 
triplicate experiments, normalized by using vinculin expression as loading 
control.  
ns: not significant compared to control. 
Significance are indicated by *p<0.05; **p<0.01; ***p<0.001.  
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Figure 6 – Caspase activation and Parp degradation in SK-MEL-5 and A375 
melanoma cells after DM-1 exposure. Total extracts were used to analyzed the 
inactive proform of caspases 9 and 3, the active form of caspase 9, Parp and 
cleaved Parp protein levels after DM-1 treatment at 3, 6 and 24 h. Vinculin was 
used as a loading control. 
